Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Subretinal Injection of LX102 in Participants With Neovascular Age-Related Macular Degeneration - The STELLAR Trial

NCT07317934 is registered in ClinicalTrials.gov with Innostellar Biotherapeutics Co.,Ltd as lead sponsor.

NCT NCT07317934
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07317934 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Subretinal Injection of LX102 in Participants With Neovascular Age-Related Macular Degeneration - The STELLAR Trial
Lead sponsor
Innostellar Biotherapeutics Co.,Ltd
Phase
Phase 3
Overall status
Recruiting
Start date
January 14, 2026
Completion date
June 4, 2032
Enrollment
388 (estimated)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration (namd), wet amd